Use of Bayesian Multivariate Meta-Analysis to Estimate the HAQ for Mapping Onto the EQ-5D Questionnaire in Rheumatoid Arthritis

被引:14
作者
Bujkiewicz, Sylwia [1 ]
Thompson, John R. [2 ]
Sutton, Alex J. [1 ]
Cooper, Nicola J. [1 ]
Harrison, Mark J. [3 ]
Symmons, Deborah P. M. [4 ]
Abrams, Keith R. [1 ]
机构
[1] Univ Leicester, Dept Hlth Sci, Biostat Res Grp, Leicester LE1 7RH, Leics, England
[2] Univ Leicester, Dept Hlth Sci, Genet Epidemiol Grp, Leicester LE1 7RH, Leics, England
[3] Univ Manchester, Inst Populat Hlth, Manchester Ctr Hlth Econ, Manchester, Lancs, England
[4] Univ Manchester, Sch Translat Med, Arthrit Res UK Epidemiol Unit, NIHR Manchester Musculoskeletal Biomed Res Unit, Manchester, Lancs, England
基金
英国医学研究理事会;
关键词
Bayesian analysis; health technology assessment; meta-analysis; multiple end points; rheumatoid arthritis; surrogate end points; HEALTH-ASSESSMENT QUESTIONNAIRE; QUALITY-OF-LIFE; COST-EFFECTIVENESS; CLINICAL-PRACTICE; INFLIXIMAB TREATMENT; UTILITY VALUES; STURE REGISTRY; VICE-VERSA; OPEN-LABEL; ETANERCEPT;
D O I
10.1016/j.jval.2013.11.005
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: In health technology assessment, decisions about reimbursement for new health technologies are largely based on effectiveness estimates. Sometimes, however, the target effectiveness estimates are not readily available. This may be because many alternative instruments measuring these outcomes are being used (and not all always reported) or an extended follow-up time of clinical trials is needed to evaluate long-term end points, leading to the limited data on the target clinical outcome. In the areas of highest priority in health care, decisions are required to be made on a short time scale. Therefore, alternative clinical outcomes, including surrogate end points, are increasingly being considered for use in evidence synthesis as part of economic evaluation. Objective: To illustrate the potential effect of reduced uncertainty around the clinical outcome on the utility when estimating it from a multivariate meta-analysis. Methods: Bayesian multivariate meta-analysis has been used to synthesize data on correlated outcomes in rheumatoid arthritis and to incorporate external data in the model in the form of informative prior distributions. Estimates of Health Assessment Questionnaire were then mapped onto the health-related quality-of-life measure EuroQol five dimensional questionnaire, and the effect was compared with mapping the Health Assessment Questionnaire obtained from the univariate approach. Results: The use of multivariate meta-analysis can lead to reduced uncertainty around the effectiveness parameter and ultimately uncertainty around the utility. Conclusions: By allowing all the relevant data to be incorporated in estimating clinical effectiveness outcomes, multivariate meta-analysis can improve the estimation of health utilities estimated through mapping methods. While reduced uncertainty may have an effect on decisions based on economic evaluation of new health technologies, the use of short-term surrogate end points can allow for early decisions. More research is needed to determine the circumstances under which uncertainty is reduced.
引用
收藏
页码:109 / 115
页数:7
相关论文
共 52 条
[1]  
[Anonymous], MVMETA MULTIVARIATE
[2]   Mapping FACT-Melanoma Quality-of-Life Scores to EQ-5D Health Utility Weights [J].
Askew, Robert L. ;
Swartz, Richard J. ;
Xing, Yan ;
Cantor, Scott B. ;
Ross, Merrick I. ;
Gershenwald, Jeffrey E. ;
Palmer, J. Lynn ;
Lee, Jeffrey E. ;
Cormier, Janice N. .
VALUE IN HEALTH, 2011, 14 (06) :900-906
[3]   Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden [J].
Bansback, NJ ;
Brennan, A ;
Ghatnekar, O .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) :995-1002
[4]   Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure [J].
Bennett, AN ;
Peterson, P ;
Zain, A ;
Grumley, J ;
Panayi, G ;
Kirkham, B .
RHEUMATOLOGY, 2005, 44 (08) :1026-1031
[5]   Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study [J].
Bingham, Clifton O., III ;
Ince, Akgun ;
Haraoui, Boulos ;
Keystone, Edward C. ;
Chon, Yun ;
Baumgartner, Scott .
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (05) :1131-1142
[6]   Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice [J].
Bombardieri, S. ;
Ruiz, A. A. ;
Fardellone, P. ;
Geusens, P. ;
McKenna, F. ;
Unnebrink, K. ;
Oezer, U. ;
Kary, S. ;
Kupper, H. ;
Burmester, G. R. .
RHEUMATOLOGY, 2007, 46 (07) :1191-1199
[7]   Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept [J].
Buch, Maya H. ;
Bingham, Sarah J. ;
Bejarano, Victoria ;
Bryer, Domini ;
White, Jo ;
Emery, Paul ;
Reece, Richard ;
Quinn, Mark .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (03) :448-453
[8]   C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis - Defining subtypes of nonresponse and subsequent response to etanercept [J].
Buch, MH ;
Seto, Y ;
Bingham, SJ ;
Bejarano, V ;
Bryer, D ;
White, J ;
Emery, P .
ARTHRITIS AND RHEUMATISM, 2005, 52 (01) :42-48
[9]   Multivariate meta-analysis of mixed outcomes: a Bayesian approach [J].
Bujkiewicz, Sylwia ;
Thompson, John R. ;
Sutton, Alex J. ;
Cooper, Nicola J. ;
Harrison, Mark J. ;
Symmons, Deborah P. M. ;
Abrams, Keith R. .
STATISTICS IN MEDICINE, 2013, 32 (22) :3926-3943
[10]   Development of a Transparent Interactive Decision Interrogator to Facilitate the Decision-Making Process in Health Care [J].
Bujkiewicz, Sylwia ;
Jones, Hayley E. ;
Lai, Monica C. W. ;
Cooper, Nicola J. ;
Hawkins, Neil ;
Squires, Hazel ;
Abrams, Keith R. ;
Spiegelhalter, David J. ;
Sutton, Alex J. .
VALUE IN HEALTH, 2011, 14 (05) :768-776